A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) [satavaptan] on Serum Sodium in Patients With Dilutional Hyponatremia.

Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) [satavaptan] on Serum Sodium in Patients With Dilutional Hyponatremia.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2011

At a glance

  • Drugs Satavaptan (Primary)
  • Indications Hyponatraemia
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms DILIPO
  • Most Recent Events

    • 03 Jan 2011 Results published in the European Journal of Heart Failure
    • 07 Jul 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top